Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
44
ARMP Quote, Financials, Valuation and Earnings
Last price:
$6.15
Seasonality move
:
17%
Day range:
$6.09 - $6.41
52-week range:
$0.90 - $16.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
51.01x
P/B ratio:
--
Volume:
7.5K
Avg. volume:
61.9K
1-year change:
214.2%
Market cap:
$223.4M
Revenue:
$5.2M
EPS (TTM):
-$1.32
Analysts' Opinion
-
Consensus RatingArmata Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.00, Armata Pharmaceuticals, Inc. has an estimated upside of 43.31% from its current price of $6.41.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.00 representing 100% downside risk from its current price of $6.41.
Fair Value
-
According to the consensus of 1 analyst, Armata Pharmaceuticals, Inc. has 43.31% upside to fair value with a price target of $9.00 per share.
ARMP vs. S&P 500
-
Over the past 5 trading days, Armata Pharmaceuticals, Inc. has overperformed the S&P 500 by 8.25% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Armata Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Armata Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Armata Pharmaceuticals, Inc. reported revenues of $1.2M.
Earnings Growth
-
Armata Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Armata Pharmaceuticals, Inc. reported earnings per share of -$0.74.
Enterprise value:
391.1M
EV / Invested capital:
4.76x
Price / LTM sales:
51.01x
EV / EBIT:
14.59x
EV / Revenue:
77.38x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-14.26x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
13.09x
Gross Profit (TTM):
$3.6M
Return On Assets:
-51.53%
Net Income Margin (TTM):
-928%
Return On Equity:
--
Return On Invested Capital:
-57.86%
Operating Margin:
-670.92%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $4.1M | $5.5M | $5.1M | $3M | $1.2M | |
| Gross Profit | $3.2M | $4.2M | $3.6M | $2.7M | $789K | |
| Operating Income | -$41.6M | -$41.5M | -$33.4M | -$9.8M | -$7.8M | |
| EBITDA | -$40.7M | -$40.3M | -$31.9M | -$9.5M | -$7.4M | |
| Diluted EPS | -$1.65 | -$1.64 | -$1.32 | -$0.15 | -$0.74 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $14.2M | $33.2M | $36.6M | $22.4M | $16.9M | |
| Total Assets | $42.7M | $92.9M | $112.8M | $98.2M | $89.5M | |
| Current Liabilities | $5.3M | $7M | $21.9M | $118.2M | $140M | |
| Total Liabilities | $18.9M | $47.3M | $125.1M | $149.2M | $185.1M | |
| Total Equity | $23.8M | $45.6M | -$12.4M | -$51M | -$95.6M | |
| Total Debt | $10.6M | $37.2M | $100.2M | $135.3M | $173.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$49.8M | -$37.7M | -$27M | -$8.9M | -$4.3M | |
| Cash From Investing | -$5.3M | -$4.3M | -$413K | -$340K | -$242K | |
| Cash From Financing | $53.5M | $34.9M | $25M | -$61K | $15M | |
| Free Cash Flow | -$55.1M | -$42.1M | -$27.4M | -$9.2M | -$4.5M | |
ARMP
Sector
Market Cap
$223.4M
$28.1M
Price % of 52-Week High
37.64%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-5.84%
-1.49%
1-Year Price Total Return
223.71%
-17.13%
Beta (5-Year)
1.240
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$5.97
200-day SMA
Buy
Level
$3.06
Bollinger Bands (100)
Buy
Level
2.6 - 6.02
Chaikin Money Flow
Sell
Level
-2.8M
20-day SMA
Buy
Level
$6.11
Relative Strength Index (RSI14)
Buy
Level
54.79
ADX Line
Buy
Level
28.27
Williams %R
Sell
Level
-17.2197
50-day SMA
Buy
Level
$5.81
MACD (12, 26)
Buy
Level
0.04
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
47.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.1506)
Sell
CA Score
(Annual)
Level (-6.327)
Buy
Beneish M-Score
(Annual)
Level (-2.4041)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (10.4149)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (4)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.
Stock Forecast FAQ
In the current month, ARMP has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ARMP average analyst price target in the past 3 months is $9.00.
-
Where Will Armata Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Armata Pharmaceuticals, Inc. share price will rise to $9.00 per share over the next 12 months.
-
What Do Analysts Say About Armata Pharmaceuticals, Inc.?
Analysts are divided on their view about Armata Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Armata Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $9.00.
-
What Is Armata Pharmaceuticals, Inc.'s Price Target?
The price target for Armata Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $9.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ARMP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Armata Pharmaceuticals, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of ARMP?
You can purchase shares of Armata Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Armata Pharmaceuticals, Inc. shares.
-
What Is The Armata Pharmaceuticals, Inc. Share Price Today?
Armata Pharmaceuticals, Inc. was last trading at $6.15 per share. This represents the most recent stock quote for Armata Pharmaceuticals, Inc.. Yesterday, Armata Pharmaceuticals, Inc. closed at $6.41 per share.
-
How To Buy Armata Pharmaceuticals, Inc. Stock Online?
In order to purchase Armata Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ARMP Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ARMP
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
--
1.81x
Price / LTM sales
51.01x
1.59x
Growth Metrics
ARMP
Sector
Revenue growth
-61.02%
4.62%
Earnings growth
-386.01%
11.06%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.42
-$0.21
Profitability
ARMP
Sector
Profitability FY 2024
$3.8M
$3.6M
Return on invested capital
-57.86%
-31.84%
Return on assets
-51.53%
-27.96%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Feb
11
Balance Sheet
ARMP
Sector
Total cash
$14.8M
$26.4M
Short term investments
--
$25.7M
Total assets
$99.3M
$76.9M
Long term debt
$173.2M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
